Search Result

Search Result

Results for "

IRAK4 degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Autophagy (2) E3 Ligase Ligand-Linker Conjugates (2) IRAK (14) Ligands for Target Protein for PROTAC (1) PROTAC Linkers (1) PROTACs (11)
By Research Areas:	Cancer (23) Inflammation/Immunology (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

*PROTAC IRAK4* degrader-1** 1 Publications Verification	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively .

HY-135382A

PROTAC IRAK4 degrader-3

IRAK PROTACs Inflammation/Immunology

PROTAC IRAK4 degrader-3 is a PROTAC-induced IRAK4 degrader based on von Hippel-Lindau .

*PROTAC IRAK4* degrader-2**	PROTACs IRAK	Inflammation/Immunology Cancer
PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC₅₀ in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC₅₀ of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .

HY-153673

PROTAC IRAK4 degrader-8

IRAK Cancer

PROTAC IRAK4 degrader-8 (compound 2) is a PROTAC targeting to IRAK4 (IC₅₀=15.5 nM) .
HY-139316

PROTAC IRAK4 degrader-5

IRAK PROTACs Cancer

PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4 degrader extracted from patent US20190192668A1, compound I-171 .

*PROTAC IRAK4* degrader-4**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .

*PROTAC IRAK4* degrader-6**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .

KT-474 KYM-001; PROTAC IRAK4 degrader-7	PROTACs IRAK Apoptosis	Cancer
KT-474 (KYM-001) is an orally active PROTAC IRAK4 degrader with antitumor activities . KT-474 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148276

KTX-497

IRAK Cancer

KTX-497 is an IRAK4 degrader with a DC₅₀ value of 3 nM. KTX-497 can be used for the research of oncology .
HY-148277

KTX-612

IRAK Cancer

KTX-612 is an orally active IRAK4 degrader with a DC₅₀ value of 7 nM. KTX-612 can be used for the research of oncology .

PROTAC IRAK4 ligand-1	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

HY-145484

PROTAC IRAK4 ligand-3

PROTACs Cancer

PROTAC IRAK4 ligand-3 is a ligand of PROTAC IRAK4 degrader-7 (HY-145483). PROTAC IRAK4 ligand-3 can be used for the research of cancer .

Thalidomide 5-fluoride	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide 5-fluoride is Thalidomide-based cereblon ligand that incorporates to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.

HY-148275

KTX-955

IRAK Cancer

KTX-955 is a potent IRAK4 degrader with DC₅₀ values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively. KTX-955 can be used to research anticancer .

Thalidomide 4-fluoride Cereblon ligand 4; E3 ligase Ligand 4	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966) .

KTX-582 intermediate-2	Others	Cancer
KTX-582 intermediate-2 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC_{50_{of 4 nM and 5 nM for IRAK4 and Ikaros, respectively ^{[1] ^.}}}

KTX-582 intermediate-3	Others	Cancer
KTX-582 intermediate-3 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC₅₀ of 4 nM and 5 nM for IRAK4 and Ikaros, respectively .

KTX-582 intermediate-1	Others	Cancer
KTX-582 intermediate-1 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC_{50_{of 4 nM and 5 nM for IRAK4 and Ikaros, respectively ^{[1] ^.}}}

KTX-582	PROTACs IRAK Apoptosis	Cancer
KTX-582 is a potent *IRAK4* degrader with DC₅₀ values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88 ^MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model .

HY-129968

AM-Imidazole-PA-Boc

PROTAC Linkers Cancer

AM-Imidazole-PA-Boc is an alkyl chain-based PROTAC linker can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

KTX-951	PROTACs IRAK	Cancer
KTX-951 is a PROTAC targeting *IRAK4* degradation (DC₅₀=18 nM). KTX-951 (10 mg/kg) shows the oral bioavailability (F%) of 22% in a rat model. KTX-951 has good anticancer potential .

JNJ-1013	Apoptosis IRAK	Cancer
JNJ-1013 is a potent and selective *IRAK1* degrader with an IC₅₀s of 72, 443, 1071 nM for IRAK1, IRAK4, VHL FP respectively. JNJ-1013 induces Apoptosis and increases the expression of cleavaged PARP. JNJ-1013 decreases the expression IRAK1, p-IKBα, pSTAT3(Tyr705) .

KTX-582 intermediate-4	Others	Cancer
KTX-582 intermediate-4 (intermediate 2-1)is a synthesis IRAK4Degrading agent KTX-582 (HY-148274)of intermediates. KTX-582It is also an effective form of apoptosis (apoptosis)inducer .

FMF-06-098-1	PROTACs	Cancer
FMF-06-098-1 is a multitargeted depressant. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us